Beauty Health Analyst Ratings
Beauty Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/25/2023 | 64.47% | Canaccord Genuity | → $10 | Assumes | → Buy |
| 08/10/2023 | 48.03% | TD Cowen | $15 → $9 | Maintains | Outperform |
| 08/10/2023 | 171.38% | DA Davidson | $35 → $16.5 | Maintains | Buy |
| 08/08/2023 | 278.29% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 06/21/2023 | 64.47% | Stifel | $17 → $10 | Downgrades | Buy → Hold |
| 05/26/2023 | 97.37% | JP Morgan | $13 → $12 | Maintains | Neutral |
| 05/18/2023 | 278.29% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 05/11/2023 | 475.66% | DA Davidson | → $35 | Reiterates | → Buy |
| 03/28/2023 | 196.05% | Canaccord Genuity | → $18 | Reiterates | → Buy |
| 03/20/2023 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
| 03/14/2023 | 278.29% | Benchmark | → $23 | Reiterates | → Buy |
| 03/01/2023 | 475.66% | DA Davidson | $32 → $35 | Maintains | Buy |
| 02/28/2023 | 278.29% | Benchmark | → $23 | Reiterates | → Buy |
| 02/16/2023 | 146.71% | Cowen & Co. | $20 → $15 | Maintains | Outperform |
| 11/23/2022 | 212.5% | Goldman Sachs | $22 → $19 | Maintains | Buy |
| 11/09/2022 | 80.92% | JP Morgan | $22 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2022 | 426.32% | DA Davidson | $31 → $32 | Maintains | Buy |
| 09/28/2022 | 409.87% | DA Davidson | $30 → $31 | Maintains | Buy |
| 09/16/2022 | 278.29% | Piper Sandler | $20 → $23 | Maintains | Overweight |
| 09/16/2022 | 393.42% | DA Davidson | $25 → $30 | Maintains | Buy |
| 08/16/2022 | 261.84% | Goldman Sachs | $25 → $22 | Maintains | Buy |
| 08/10/2022 | 228.95% | Piper Sandler | $22 → $20 | Maintains | Overweight |
| 08/10/2022 | 311.18% | DA Davidson | $24 → $25 | Maintains | Buy |
| 07/08/2022 | 261.84% | Piper Sandler | $24 → $22 | Maintains | Overweight |
| 06/30/2022 | 228.95% | Canaccord Genuity | $22 → $20 | Maintains | Buy |
| 05/12/2022 | 294.74% | DA Davidson | $35 → $24 | Maintains | Buy |
| 05/11/2022 | 311.18% | Goldman Sachs | $29 → $25 | Maintains | Buy |
| 05/11/2022 | 294.74% | Piper Sandler | $26 → $24 | Maintains | Overweight |
| 04/28/2022 | 327.63% | Piper Sandler | $31 → $26 | Maintains | Overweight |
| 03/14/2022 | 278.29% | Benchmark | $18 → $23 | Maintains | Buy |
| 03/11/2022 | 294.74% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 475.66% | DA Davidson | $32 → $35 | Maintains | Buy |
| 01/07/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/23/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 11/10/2021 | 426.32% | DA Davidson | $26 → $32 | Maintains | Buy |
| 10/08/2021 | 442.76% | Stifel | → $33 | Initiates Coverage On | → Buy |
| 10/04/2021 | 426.32% | Cowen & Co. | → $32 | Initiates Coverage On | → Outperform |
| 08/11/2021 | 327.63% | DA Davidson | $17.5 → $26 | Maintains | Buy |
| 07/19/2021 | 261.84% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 07/01/2021 | 409.87% | Goldman Sachs | → $31 | Initiates Coverage On | → Buy |
| 06/24/2021 | 294.74% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 245.39% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 06/01/2021 | 187.83% | DA Davidson | $16 → $17.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月25日 | 64.47% | 卡納科特·格納奇 | →$10 | 假設 | →購買 |
| 2023年08月10日 | 48.03% | TD Cowen | $15→$9 | 維護 | 跑贏大盤 |
| 2023年08月10日 | 171.38% | 達·戴維森 | $35→$16.5 | 維護 | 買 |
| 2023/08/08 | 278.29% | 基準 | →$23 | 重申 | 購買→購買 |
| 2023年6月21日 | 64.47% | Stifel | $17→$10 | 評級下調 | 購買→Hold |
| 2023年05月26日 | 97.37% | 摩根大通 | $13→$12 | 維護 | 中性 |
| 2023年05月18日 | 278.29% | 基準 | →$23 | 重申 | 購買→購買 |
| 2023年05月11日 | 475.66% | 達·戴維森 | →$35 | 重申 | →購買 |
| 03/28/2023 | 196.05% | 卡納科特·格納奇 | →$18 | 重申 | →購買 |
| 03/20/2023 | - | 法國巴黎銀行 | 升級 | 表現不佳的→中性 | |
| 03/14/2023 | 278.29% | 基準 | →$23 | 重申 | →購買 |
| 03/01/2023 | 475.66% | 達·戴維森 | $32→$35 | 維護 | 買 |
| 02/28/2023 | 278.29% | 基準 | →$23 | 重申 | →購買 |
| 02/16/2023 | 146.71% | 考恩公司 | $20→$15 | 維護 | 跑贏大盤 |
| 2022年11月23日 | 212.5% | 高盛 | $22→$19 | 維護 | 買 |
| 11/09/2022 | 80.92% | 摩根大通 | $22→$11 | 評級下調 | 超重→中性 |
| 11/09/2022 | 426.32% | 達·戴維森 | $31→$32 | 維護 | 買 |
| 09/28/2022 | 409.87% | 達·戴維森 | $30→$31 | 維護 | 買 |
| 09/16/2022 | 278.29% | 派珀·桑德勒 | $20→$23 | 維護 | 超重 |
| 09/16/2022 | 393.42% | 達·戴維森 | $25→$30 | 維護 | 買 |
| 08/16/2022 | 261.84% | 高盛 | $25→$22 | 維護 | 買 |
| 2022年08月10日 | 228.95% | 派珀·桑德勒 | $22→$20 | 維護 | 超重 |
| 2022年08月10日 | 311.18% | 達·戴維森 | $24→$25 | 維護 | 買 |
| 07/08/2022 | 261.84% | 派珀·桑德勒 | $24→$22 | 維護 | 超重 |
| 2022/06/30 | 228.95% | 卡納科特·格納奇 | $22→$20 | 維護 | 買 |
| 2022年05月12日 | 294.74% | 達·戴維森 | $35→$24 | 維護 | 買 |
| 2022年05月11日 | 311.18% | 高盛 | $29→$25 | 維護 | 買 |
| 2022年05月11日 | 294.74% | 派珀·桑德勒 | $26→$24 | 維護 | 超重 |
| 04/28/2022 | 327.63% | 派珀·桑德勒 | $31→$26 | 維護 | 超重 |
| 03/14/2022 | 278.29% | 基準 | $18→$23 | 維護 | 買 |
| 03/11/2022 | 294.74% | 摩根大通 | →$24 | 開始承保 | →超重 |
| 02/23/2022 | 475.66% | 達·戴維森 | $32→$35 | 維護 | 買 |
| 01/07/2022 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 2021年12月23日 | - | 雷蒙德·詹姆斯 | 開始承保 | →市場表現 | |
| 2021年11月10日 | 426.32% | 達·戴維森 | $26→$32 | 維護 | 買 |
| 10/08/2021 | 442.76% | Stifel | →$33 | 開始承保 | →購買 |
| 10/04/2021 | 426.32% | 考恩公司 | →$32 | 開始承保 | →跑贏大盤 |
| 2021/08/11 | 327.63% | 達·戴維森 | $17.5→$26 | 維護 | 買 |
| 07/19/2021 | 261.84% | 傑富瑞 | →$22 | 開始承保 | →購買 |
| 07/01/2021 | 409.87% | 高盛 | →$31 | 開始承保 | →購買 |
| 06/24/2021 | 294.74% | 派珀·桑德勒 | →$24 | 開始承保 | →超重 |
| 2021/06/15 | 245.39% | 卡納科特·格納奇 | →$21 | 開始承保 | →購買 |
| 06/01/2021 | 187.83% | 達·戴維森 | $16→$17.5 | 維護 | 買 |
What is the target price for Beauty Health (SKIN)?
美容健康(皮膚)的目標價格是多少？
The latest price target for Beauty Health (NASDAQ: SKIN) was reported by Canaccord Genuity on August 25, 2023. The analyst firm set a price target for $10.00 expecting SKIN to rise to within 12 months (a possible 64.47% upside). 20 analyst firms have reported ratings in the last year.
2023年8月25日，Canaccel Genuity報道了美容健康(納斯達克：皮膚)的最新目標價。這家分析公司將目標價定為10.00美元，預計皮膚價格將在12個月內上漲至64.47%(可能上漲64.47%)。去年，已有20家分析公司公佈了評級。
What is the most recent analyst rating for Beauty Health (SKIN)?
美容健康(皮膚)的最新分析師評級是多少？
The latest analyst rating for Beauty Health (NASDAQ: SKIN) was provided by Canaccord Genuity, and Beauty Health their buy rating.
美容健康(納斯達克代碼：Skin)的最新分析師評級由Canaccel Genuity提供，美容健康的最新評級為買入。
When is the next analyst rating going to be posted or updated for Beauty Health (SKIN)?
美容健康(皮膚)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beauty Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beauty Health was filed on August 25, 2023 so you should expect the next rating to be made available sometime around August 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Beauty Health的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。上一次對美容健康的評級是在2023年8月25日提交的，所以你應該預計下一次評級將在2024年8月25日左右公佈。
Is the Analyst Rating Beauty Health (SKIN) correct?
分析師對美容健康(皮膚)的評級正確嗎？
While ratings are subjective and will change, the latest Beauty Health (SKIN) rating was a with a price target of $0.00 to $10.00. The current price Beauty Health (SKIN) is trading at is $6.08, which is within the analyst's predicted range.
雖然評級是主觀的，而且會發生變化，但最新的美容健康(皮膚)評級是A，目標價在0.00美元到10.00美元之間。美容健康(皮膚)目前的交易價格為6.08美元，在分析師的預測範圍內。